Erkan ÜNSAL
(İstanbul Eğitim ve Araştırma Hastanesi, Göz Hastalıkları, İstanbul, Türkiye)
Mehmet Özgür ÇUBUK
(İstanbul Eğitim ve Araştırma Hastanesi, Göz Hastalıkları, İstanbul, Türkiye)
Armağan FİLİK
(İstanbul Eğitim ve Araştırma Hastanesi, Göz Hastalıkları, İstanbul, Türkiye)
Furkan ÇİFTÇİ
(İstanbul Eğitim ve Araştırma Hastanesi, Göz Hastalıkları, İstanbul, Türkiye)
Yıl: 2019Cilt: 28Sayı: 3ISSN: 1300-1256 / 2717-7149Sayfa Aralığı: 259 - 264İngilizce

36 0
The Outcomes of Pars Plana Vitrectomy For Diabetic Vitreous Hemorrhage: The Effect of Preoperative Intravitreal Anti Vascular Endothelial Growth Factor Agents
Purpose: To analyze the effect of preoperative intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents on intraoperative and postoperative complications of pars plana vitrectomy (PPV) applying for diabetic vitreous hemorrhage treatment. Method: A retrospective study was designed to evaluate the effect of preoperative anti-VEGF agents. Patients treated with PPV for proliferative diabetic retinopathy related nonclearing vitreous hemorrhage were enrolled in this study. Patients received an intravitreal anti-VEGF injection (repackaged 1.25 mg/0.05 ml bevacizumab, 0.5 mg/0.05 mL ranibizumab, 2 mg/0.05 ml afl ibercept) before surgery (1 to 14 days before surgery) were included in group 1. Patients did not receive an anti-VEGF injection were included in group 2. Different groups were compared in terms of intraoperative and postoperative complications and duration of surgery. Results: Fifty-nine eyes of 59 patients have fulfi lled the inclusion criteria and were analyzed in this study. Thirty eyes of 30 patients were included in group 1, and 29 eyes of 29 patients were included in group 2. Final best-corrected visual acuity (BCVA) after surgery showed signifi cant improvement compared with baseline in 2 groups (p=0.001). Incidence of signifi cant intraoperative bleeding and the incidence of the iatrogenic retinal tear was higher in group 2 (p=0.045, p=0.049 respectively). Incidence of early and delayed recurrent vitreous hemorrhage (VH) did not differ signifi cantly between the 2 treatment groups (p=0.76, p=0.61 respectively). The duration of surgery in group 1 was signifi cantly shorter than group 2, (p=0.001). Conclusion: The preoperative anti-VEGF agents applying for diabetic VH facilitate a faster the surgery and achieve better operative results
DergiAraştırma MakalesiErişime Kapalı
  • Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 2007;14:179–83.
  • Zhao XY, Xia S, Chen YX. Antivascular endothelial growth factor agents pretreatment before vitrectomy for complicatedproliferative diabetic retinopathy: a metaanalysis of randomised controlled trials. Br J Ophthalmol. 2018 Aug;102(8):1077-1085
  • Blankenship GW, Machemer R. Long-term diabetic vitrectomy results. Report of 10 year follow-up. Ophthalmology 1985;92:503–6.
  • Yang X, Xu J, Wang R, et al. A randomized controlled trial of conbercept pretreatment before vitrectomy in proliferative diabetic retinopathy. J Ophthalmol 2016;2016:1–8.
  • Novak MA, Rice TA, Michels RG, Auer C. Vitreous hemorrhage after vitrectomy for diabetic retinopathy. Ophthalmology 1984;91:1485-9.
  • Yang CM, Yeh PT, Yang CH. Intravitreal longacting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology 2007;114:710-5.
  • West JF, Gregor ZJ. Fibrovascular ingrowth and recurrent haemorrhage following diabetic vitrectomy. Br J Ophthalmol 2000;84:822-5.
  • Brown GC, Tasman WS, Benson WE, McNamara JA, Eagle RC Jr. Reoperation following diabetic vitrectomy. Arch Ophthalmol 1992;110:506-10.
  • Tolentino FI, Cajita VN, Gancayco T, Skates S. Vitreous hemorrhage after closed vitrectomy for proliferative diabetic retinopathy. Ophthalmology 1989;96:1495-500.
  • Blankenship GW. Management of vitreous cavity hemorrhage following pars plana vitrectomy for diabetic retinopathy. Ophthalmology 1986;93:39-44.
  • Zaninetti M, Petropoulos IK, Pournaras CJ. Proliferative diabetic retinopathy: Vitreoretinal complications are often related to insuffi cient retinal photocoagulation. J Fr Ophtalmol 2005;28:381-4.
  • Shi L, Huang YF. Postvitrectomy diabetic vitreous hemorrhage in proliferative diabeticretinopathy. J Res Med Sci 2012;17:865–71.
  • Batıoğlu F, Diabetik Retinopati - Anti-Vegf Tedavi. Ret-Vit Özel Sayı 2014;22:74-78.
  • Morera Y, González R, Lamdan H, et al. Vaccination with a mutated variant of human Vascular Endothelial Growth Factor (VEGF) blocks VEGF-induced retinal neovascularization in a rabbit experimental model. Exp Eye Res 2014;122:102–9.
  • Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev 2015 Aug 7;(8):CD008214.
  • Pakzad-Vaezi K, Albiani DA, Kirker AW, et al. A randomized study comparing the effi cacy of bevacizumab and ranibizumab as pre-treatment for pars plana vitrectomy in proliferative diabetic retinopathy. Ophthalmic Surg Lasers Imaging Retina 2014;45:521–4.
  • Simunovic MP, Maberley DA. Anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy: a systematic review and meta-analysis. Retina 2015;35:1931–42.
  • Comyn O, Wickham L, Charteris DG, et al. Ranibizumab pretreatment in diabetic vitrectomy: a pilot randomised controlled trial (the RaDiVit study). Eye 2017;31:1253–8.
  • Farahvash MS, Majidi AR, Roohipoor R, Ghassemi F. Preoperative injection of intravitreal bevacizumab in dense diabetic vitreous hemorrhage. Retina 2011;31:1254–60.
  • Ahn J, Woo SJ, Chung H, Park KH. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. Ophthalmology 2011;118:2218–26.
  • Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445–50.
  • Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fl uid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480–7.
  • Li X, Zarbin MA, Bhagat N. Anti-Vascular Endothelial Growth Factor Injections: The New Standard of Care in Proliferative Diabetic Retinopathy? Dev Ophthalmol. 2017;60:131-142
  • da R Lucena D, Ribeiro JA, Costa RA, et al. Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). Br J Ophthalmol 2009;93:688 –91.
  • El-Batarny AM. Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy. Clin Ophthalmol 2008;2: 709–716.
  • Modarres M, Nazari H, Falavarjani KG, Naseripour M, Hashemi M, Parvaresh MM. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol 2009;19:848–852.
  • Murat Yolar, Cengiz Aras, Ceyhun Arıcı. Ağır Proliferatif Karakterdeki Diyabetik Retinopatili Olgularda intravitreal Bevacizumab Enjeksiyonunu Takiben Bimanuel Teknikle Pars Plana Vitrektomi. Cerrahpaşa Tıp Dergisi 2009; 40(2): 72-76.
  • Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 2008;246:837–842.
  • Su L, Ren X, Wei H et al. Intravitreal Conbercept (Kh902) For Surgical Treatment Of Severe Proliferative Dibatic Retinopathy. Retina. 2016 May;36(5):938-43.
  • Arevalo JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008;92:213–216.
  • Van Geest RJ, Lesnik-Oberstein SY, Tan HS, et al. A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofi brotic switch in proliferative diabetic retinopathy. Br J Ophthalmol 2012;96:587–90.
  • MahalingamP, TopiwallaTT, GanesanG.Vitreous rebleed following sutureless vitrectomy: Incidence and risk factors. Indian J Ophthalmol. 2018 Apr;66(4):558-561.
  • Doğanay S, Koç B, Çankaya C, Düz C, Bilak Ş. Diyabetik Olgularda Pars Plana Vitrektomiden Önce Uygulanan İntravitreal Bevacizumabın Cerrahi Başarıya Etkisi. Ret-Vit 2010;18:310-313.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.